Preparation, Optimization and in vitro Evaluation of Glipizide Nanoparticles Integrated with Eudragit RS-100

P. Saharan¹, K. Bahmani²,* and S.P. Saharan¹

¹Department of Pharmaceutical Sciences, Faculty of Pharmacy, Guru Jambheshwar University of Science & Technology, Hisar, Haryana-125001, India; ²Department of Pharmaceutical Sciences, Faculty of Pharmacy, Ch. Bansi Lal University, Bhiwani, Haryana, India

Abstract: Background: Solubility is an important criterion for drug efficacy, independent of the route of administration. It also poses a major challenge for pharmaceutical industries, which are developing new pharmaceutical products, since 40% of the active substances being identified are either insoluble or poorly soluble in aqueous media.

Objective: The objective of this study was to develop nanoformulation of glipizide drug-loaded nanoparticles providing controlled release formulation.

Method: Nanoparticles were prepared by the solvent evaporation method. Eudragit RS100, a nonbiodegradable polymer with varying ratios was used for making the formulation. The effect of key formulation variables on the particle size and entrapment efficiency and drug loading of nanoparticles were studied by using factorial design.

Results: DSC thermograms indicate that glipizide was dispersed in an amorphous state in the polymer. TEM study indicates that the nanoparticles were in spherical shape. The mean diameter was dependent on the presence of the amount of Eudragit RS100 and viscosity of the organic phase. The in vitro study showed that the cumulative drug release was from 69.52-81.44 % in 10 hrs at pH 6.8 in phosphate buffer respectively.

Conclusion: The developed NPs could reduce dose frequency, decrease side effects, and improve patient compliance. Using factorial design, maximum entrapment efficiency with minimum particle size could be achieved with a few experiments.

Keywords: Characterization, Eudragit RS-100, glipizide, optimization, solvent evaporation, nanoparticles.

1. INTRODUCTION

Solubility is an important criterion for drug efficacy, independent of the route of administration. It also poses a major challenge for pharmaceutical industries, which are developing new pharmaceutical products, since 40% of the active substances being identified are either insoluble or poorly soluble in aqueous media. Over the last 10 years, nanoparticle (NP) engineering processes have been developed and reported for the enhancement of solubility of poorly aqueous soluble drugs [1].

Diabetes mellitus (DM) is one of the major incapacitating disorders spread worldwide, contributing to huge financial and health loses. Studies conducted in India highlighted that the prevalence of this metabolic dysfunction is high and increasing rapidly in the urban population due to sedentary lifestyle, aging, nutrition, stress, and obesity. The primary cause of Diabetes Mellitus Type 2 is that the pancreas may produce enough insulin to transport sugar into the cells, but the body may refuse to use the insulin [2]. Insulin helps unlock the cells of the body to allow the sugar to enter them so that glucose is transformed into energy. In Diabetes Type 2, the body refuses to use the insulin produced so insulin is unable to let the sugar enter the cells and transform into energy. The sec-
Secondary reason is insufficient for the production of insulin by the pancreas. The second generation hypoglycemic agents are used for Non-Insulin Dependent Diabetes Mellitus (NIDDM) [3, 4].

glipizide is an oral hypoglycemic agent, which is a commonly prescribed drug for the treatment of patients with type II diabetes. It is used as an adjunct to diet to the management of type II (non-insulin dependent) diabetes mellitus in patients whose hyperglycemia cannot be controlled by diet and exercise alone. glipizide is a weak acid (pKa = 5.9) practically insoluble in water and acidic environment and highly permeable (class II) drugs according to the Biopharmaceutical Classification System (BCS) [5].

Biodegradable and non-biodegradable polymers are ideal carriers for the formulation of nanoparticles. Most biodegradable polymers consist of synthetic polyesters like polycyanoacrylate or poly (D, L-lactide) and related polymers like poly (lactic acid) PLA or poly (lactide-co-glycolide) to give a few examples. The solvent evaporation method is one of the most preferred methods used for the preparation of nanoparticles [6, 7].

Eudragit polymers can be used to produce formulations which allow custom-tailored release profiles and are released over a specific period of time. Drug delivery can be controlled throughout the entire GI tract (GIT) to increase the therapeutic effect and patient compliance. Different polymer combinations of Eudragit RS-100 allow custom-tailored release profiles to achieve the desired drug delivery performance [8].

The aim of the present work is to formulate nanoparticles using Eudragit RS100 polymer using the solvent evaporation method and optimize and evaluate sustained release nanoparticles to improve its bioavailability [9, 10].

2. MATERIALS AND METHODS

2.1. Materials
Glipizide was purchased from Sigma-Aldrich. Eudragit RS100 polymer was a gift sample from Evonik Degussa India Private Limited, Mumbai. Dichloromethane, Polyvinyl alcohol and PLA polymer were also purchased from Sigma-Aldrich.

2.2. Factorial Design and Optimization
In this study, the first step was to screen using 3^2 factorial design. The second step was to optimize using 3^2 factorial designs to investigate the physicochemical properties of glipizide nanoparticles. Design-Expert (version 7.0.0; stat-Ease, Inc., Minneapolis, Minnesota, USA) was used for mathematical modeling and assessment of the response. A preliminary study was carried out based on prior knowledge from a literature survey [11, 12]. Based on the results obtained from preliminary experiments, the amount of Eudragit RS-100 (X1) and concentration of PVA (X2) was in the range of low, medium and high for independent variables which are presented in Table 1. Entrapment Efficiency (EE), Particle Size (nm) and drug loading were the response variables.

In developing the regression equation, the test factors were coded according to equation 1.

\[ X_i = (X_i - X_i^0) / \Delta X_i \]  

where \( x_i \) is the coded value of \( i^{th} \) independent variable, \( X_i \) is the natural value of the \( i^{th} \) independent variable, \( X_i^0 \) is the natural value of the \( i^{th} \) independent variable at the center points and \( \Delta X_i \) is the step change value. The multiple regressions according to the quadratic model were carried out using equation 2.

\[ Y = b_0 + \sum_i^j b_i x_i + \sum_i \sum_j y_{ij} x_i x_j + \sum_i^j b_{ij} x_i \]
where $Y$ is the measured response, $b_0$ is the intercept term, $b_i$, $b_{ij}$ and $b_{ii}$ are the measures of the variables $X_i$, $X_iX_{ij}$ and $X_i$. The variable $X_iX_{ij}$ represents the first-order interactions between $X_i$ and $X_j$ ($i<j$). Multiple regression was applied using Microsoft Excel in order to reduce the factors having a significant effect on the properties of formulations and then the best fitted mathematical model was selected on the basis of the results. The 3-D response surface plots and 2-D contour plots were studied using Design-Expert [11-13]. The results of full factorial design and observational data are given in Table 2.

### Table 2. Results of $3^2$ factorial design of glipizide loaded nanoparticles.

| Run | Amount of Polymer Eudragit RS-100 (mg) $X_1$ | Amount of Surfactant PVA (% w/v) $X_2$ | Particle Size (nm) $Y_1$ | Entrapment Efficiency (%) $Y_2$ | % Drug Loading $Y_3$ |
|-----|---------------------------------------------|----------------------------------------|--------------------------|---------------------------------|-------------------|
| 1   | 150                                         | 0.3                                    | 857                      | 62.56                           | 16.87             |
| 2   | 100                                         | 0.3                                    | 423.8                    | 77.97                           | 37.94             |
| 3   | 100                                         | 0.3                                    | 465.3                    | 77.29                           | 38.12             |
| 4   | 50                                          | 0.15                                   | 377.8                    | 64.49                           | 32.56             |
| 5   | 100                                         | 0.3                                    | 510.6                    | 77                              | 38.51             |
| 6   | 100                                         | 0.45                                   | 257.7                    | 81.23                           | 40.12             |
| 7   | 100                                         | 0.3                                    | 354.8                    | 77.81                           | 37.12             |
| 8   | 100                                         | 0.15                                   | 532.5                    | 75.12                           | 36.1              |
| 9   | 150                                         | 0.45                                   | 720.9                    | 65.18                           | 18.23             |
| 10  | 100                                         | 0.3                                    | 585.5                    | 69.75                           | 33.12             |
| 11  | 50                                          | 0.45                                   | 243                      | 77.81                           | 37.12             |
| 12  | 50                                          | 0.3                                    | 336.2                    | 71.73                           | 35.54             |
| 13  | 150                                         | 0.15                                   | 864.5                    | 58.43                           | 15.43             |

2.3. Preparations of Glipizide Nanoparticles

Solvent evaporation method was used for the preparation of glipizide nanoparticles. Firstly, the emulsification of polymeric solution was done in an aqueous solution containing a surfactant. Then the evaporation of polymeric solution was done by precipitation of the polymer. In the solution of dichloromethane (DCM), acetone drug was dissolved. With constant stirring using a magnetic stirrer, the organic solution was added into an aqueous phase containing polyvinyl alcohol. The emulsion was sonicated using probe sonicator for 6 min to get nanosize of the emulsion. The organic solvent was then evaporated using constant stirring on a magnetic stirrer for about 4-5 hrs. After centrifugation (30 min, 10000 rpm), the nanoparticles were collected. The prepared emulsion was then kept for lyophilization for 48 hrs [14-16].

2.4. Size Measurement

Nanoparticles after freeze-drying were reconstituted in distilled water. Zeta potential of nanoparticles was determined by particle size analyzer (Zeta Sizer Ver System, UK). The measurement was done in triplicate [17, 18].

2.5. Drug Loading and Entrapment Efficiency

The entrapment efficiency and drug loading of nanoparticles containing glipizide were determined by spectrophotometric determination of nanoparticles at 276 nm in a supernatant centrifuged for 30 min at 10000 rpm [19, 20].

The entrapment efficiency and drug loading was determined from following equations:

\[
\text{Entrapment Efficiency} = \frac{\text{Total amount of drug} - \text{amount of free drug}}{\text{total amount of drug added}} \times 100
\]
Drug Loading = 
\[ \frac{\text{Total amount of drug} - \text{amount of free drug}}{\text{total weight of nanoparticles}} \times 100 \] 

2.6. Drug Release Studies

A modified dialysis method was used to evaluate the in vitro release of nanoparticles. 2 ml of nanoparticles suspension was placed in a dialysis bag (cellophane membrane) which was tied and placed into 900 ml of phosphate buffer with pH 6.8, at temperature 37°C and at 100rpm in USPXXV Type II (Paddle) dissolution apparatus [21]. At selected time intervals, 5 ml aliquots were withdrawn from the medium and replaced with the same amount of buffer. The data obtained from in vitro drug release were fitted to kinetic models to understand the mechanism of drug release from the nanoparticles. The study was performed in triplicate [22].

2.7. Fourier Transform Infrared Spectroscopy (FTIR)

The FTIR study was done using Fourier Transform Infrared spectrophotometer (Shimadzu, 8400S, Japan). The test samples were mixed with KBr, pressed into a disk and scanned from 400-4000 cm⁻¹ [23].

2.8. Differential Scanning Calorimetry

The physical state characteristics of glipizide entrapped nanoparticles were characterized by Differential Scanning Calorimetry (DSC-60, Shimadzu, Japan). Each sample was selected in standard aluminum pans with lids and purged with air at a flow rate of 40 ml/min. The heat flows were recorded in the range of 30-300°C under inert nitrogen atmosphere [24].

2.9. Transmission Electron Microscopy

TEM analysis of the prepared nanoparticles was carried out to study the morphology of nanoparticles. For the study, a drop of nanoparticles suspension containing 0.01% of phosphotungstic acid was placed on a carbon film coated on a copper grid. The study was performed using Philips Technai-20, Japan. The copper grid was fixed into a sample holder and placed in a vacuum chamber of the transmission electron microscope and observed under low vacuum and the TEM images were recorded [25].

3. RESULTS AND DISCUSSION

3.1. Optimization and the Experiment

The $3^2$ factorial design was used to study the responses for all formulations on the basis of variables. The responses observed for all formulations were Particle size (Y1), Entrapment Efficiency (Y2) and Drug Loading (Y3). Table 2 shows the experimental design of Eudragit RS-100 nanoparticles and the results of measured responses. The effect of the combination of polymer and surfactant (PVA) on entrapment efficiency and drug loading was studied using the response surface plot and the results of the response surface plot are given in Figs. (1-3).

Based on the results obtained in preliminary experiments, the amount of Eudragit RS-100 (X1) and concentration of PVA (X2) were found to be major variables affecting the Particle size (Y1), Entrapment efficiency (Y2) and % Drug loading (Y3) of the nanoparticles. In case of particle size, the results showed that an increase in PS due to an increase in the polymer concentration and a decrease in the volume of organic phase [26-28]. Fig. (2) depicts the response surface plot for Drug entrapment efficiency which indicates an increase in drug entrapment due to an increase in polymer concentration and a decrease in the solvent.

3.2. Response Surface Plots

Three-dimensional response surface plots generated by the Design Expert are presented in Fig. (1) for glipizide nanoparticles. Fig. (1) depicts the response surface plots for the particle size of glipizide nanoparticle which show an increase in PS due to an increase in the polymer concentration and a decrease in the volume of organic phase. In case of drug entrapment efficiency, the results indicate that an increase in drug entrapment due to an increase in polymer concentration and a decrease in the solvent.

Quadratic model was found to be significant for particle size, entrapment efficiency and drug loading...
**Fig. (1).** Response surface plot showing combined effects of Eudragit rs-100 and pva on particle size of nanoparticles.

**Fig. (2).** Response surface plot showing combined effect of Eudragit rs-100 and pva on % entrapment efficiency of nanoparticles.
variables. Table 3 shows the model summary statistics of responses.

The relationship between the formulation variables and the responses in terms of coded factors is represented by the following equations [29, 30].

**Particle Size (Y1)** = +464.16 + 247.57* A - 92.20* B - 2.20* AB + 142.04* A² - 59.46* B²

**Entrapment Efficiency (Y2)** = +76.36 - 4.64* A + 4.36* B - 1.64* AB - 10.21* A² + 0.82* B²

**Drug Loading (Y3)** = +37.17 - 9.11* A + 1.90* B - 0.44* AB - 11.49* A² + 0.42* B²

where

A = Amount of polymer
B = Amount of surfactant (PVA)
AB = Amount of polymer (Eudragit RS100) * surfactant (PVA)

### 3.3. Solution of Numerical Optimization

On the basis of desirability approach, the numerical optimization technique was used to develop a new formulation with the desired responses of minimum particle size, maximum entrapment efficiency and maximum drug loading [31, 32]. The desirability function combines all responses in one measurement, in order to achieve the desired goal. After obtaining the desired goal, the lower limit and upper limits were set for different points as shown in Table 4.

By the numerical optimization and after confirmation of report, the formulation compositions are shown in the Table 5. The desirability approach provides a possibility to predict the optimum levels of the independent variables.

### 3.4. Determination of Particle Size and Percent Drug Entrapment

The freeze-dried nanoparticles were reconstituted in distilled water and their particle size was determined using a particle size analyzer (Zetasizer Ver System, UK). The particle size was increased by increasing the amount of polymer and this was due to the viscous nature of the polymer. The increase in the concentration of the surfactant...
Table 3. Model summary statistics of Eudragit rs100 nanoparticles formulation response to select suitable model.

| Response | Model     | Adjusted R-Squared | Predicted R-Squared | Press       | Significance       |
|----------|-----------|---------------------|---------------------|-------------|--------------------|
| Y1       | Linear    | 0.7812              | 0.6957              | 1.559E+005  | -                  |
|          | 2FI       | 0.7569              | 0.5611              | 2.248E+005  | -                  |
|          | Quadratic | 0.8743              | 0.7745              | 1.155E+005  | Suggested          |
| Y2       | Linear    | 0.2623              | -0.2019             | 760.01      | -                  |
|          | 2FI       | 0.2030              | -1.2967             | 1452.34     | -                  |
|          | Quadratic | 0.8381              | 0.7427              | 162.70      | Suggested          |
| Y3       | Linear    | 0.4518              | 0.1018              | 859.93      | -                  |
|          | 2FI       | 0.3920              | -0.8333             | 1755.27     | -                  |
|          | Quadratic | 0.9619              | 0.9570              | 41.14       | Suggested          |

Table 4. Constraints of numerical optimization (Eudragit rs100 nanoparticles).

| Name                          | Goal         | Lower Limit | Upper Limit | Lower Weight | Upper Weight | Importance |
|-------------------------------|--------------|-------------|-------------|--------------|--------------|------------|
| A: Amount of polymer          | is in range  | 50          | 150         | 1            | 1            | 3          |
| (Eudragit RS100)              |              |             |             |              |              |            |
| B: Surfactant                 | is in range  | 0.15        | 0.45        | 1            | 1            | 3          |
| Particle Size (PS)            | minimize     | 243         | 864.5       | 1            | 1            | 4          |
| % Entrapment Efficiency (EE)  | maximize     | 58.43       | 81.23       | 1            | 1            | 3          |
| % Drug Loading (DL)           | is in range  | 15.43       | 40.12       | 1            | 1            | 4          |

Table 5. Solution of numerical optimization (Eudragit RS100 Nanoparticles).

| Sr. No. | Amount of Polymer (EurS100) | Surfactant | Particle Size (PS) | % Entrapment Efficiency (EE) | % Drug Loading (DL) | Desirability | Selection |
|---------|-----------------------------|------------|-------------------|------------------------------|---------------------|--------------|-----------|
| 1       | 62.073                      | 0.450      | 208.114           | 80.440                       | 40.120              | 0.985        | Selected  |
| 2       | 60.578                      | 0.450      | 207.349           | 80.156                       | 39.874              | 0.980        | -         |
| 3       | 54.429                      | 0.450      | 206.866           | 78.795                       | 38.647              | 0.953        | -         |
| 4       | 96.347                      | 0.450      | 295.335           | 81.951                       | 40.120              | 0.951        | -         |
| 5       | 94.214                      | 0.433      | 309.557           | 81.432                       | 40.120              | 0.937        | -         |

led to a decrease in the particle size of nanoparticles (Fig. 4) [31, 32].

Entrapment efficiency and drug loading were increased with an increase in the polymer ratio (1:2). The decrease in entrapment efficiency and drug loading was studied after due to saturation capacity of polymer and formation of the more compact polymeric coat. However, drug loading and entrapment efficiency were increased with an increase in the amount of PVA. Due to large free surface, the smaller particle released the incorporated drug in faster rate which can lead to a faster
release of the drug incorporated. Nanoparticles had an average particle size of 257.7 ± 5.6 nm [33, 34].

3.5. Percentage Entrapment Efficiency and Drug Loading

The entrapment efficiency and drug loading were found to be in the range of 58.43% to 81.23% and 15.43% to 40.12% respectively. Entrapment efficiency and drug loading increased with an increase in the polymer ratio, up to a particular concentration (1:2). A decrease in entrapment efficiency and drug loading was observed after that due to the saturation capacity of the polymer and formation of the more compact polymeric coat which is shown in Figs. (5 and 6). However, the entrapment efficiency and drug loading were increased with increase in PVA concentration [35].

3.6. Fourier Transform Infrared Spectroscopy (FTIR)

The spectrum of glipizide and physical mixture of glipizide and Eudragit RS-100 is shown in Fig. (7). The FTIR spectra of Eudragit RS100 confirmed the peaks at 2981 cm⁻¹ because of CH aliphatic stretching and 1723 cm⁻¹ due to -C=O stretching. Matching of FT-IR spectrum of glipizide and Eudragit was not involved in intermolecular
interaction with the drug. The reduction in the intensity of peaks of nanoparticles formulation is probably due to weak electrostatic interaction between drug and ammonium group of polymer due to solvent evaporation. Results are shown in Table 7 [34, 35].

3.7. Differential Scanning Calorimetry (DSC)

Differential Scanning Calorimetry (DSC) is one of the general methods to study the physicochemical interaction between the drug and excipients. DSC thermograph of Eudragit RS-100 is shown in Fig. (8).
Table 7. FTIR interpretation of glipizide loaded rs100 optimized batch.

| Sr. No. | Interpretation                           | Peaks (cm\(^{-1}\))Observed |
|---------|-----------------------------------------|------------------------------|
| 1       | N-H bending                             | 1528.89                      |
| 2       | S=O stretching                          | 1333.43                      |
| 3       | N-H stretching                          | 3325.90, 3251.71             |
| 4       | C=O stretching                          | 1689.83                      |
| 5       | CONH- stretching                        | 1651.50                      |
| 6       | C=O stretching of ester group           | 1714.68                      |

Fig. (8). DSC thermogram of glipizide loaded rs 100 optimized batch.

The optimized batch showed two endothermic peaks at 174.44°C due to the presence of Eudragit RS100 and 200.71°C due to the presence of glipizide. The endothermic peak of pure glipizide was found at 207.04°C [33, 34]. There was a slight shift in the endothermic peak of glipizide in drug-loaded nanoparticles as compared to that of pure glipizide. This may be due to the drug being in an amorphous form rather than crystalline form. DSC studies show that there was compatibility between the drug and the polymers. The thermogram of optimized batch is shown in Fig. (8).

3.8. Dissolution Study

The drug release profile of the drug-loaded nanoparticles is shown in Figs. (9 and 10). Drug release studies of nanoparticles show the biphasic release profile. The release was associated with
diffusion release with an initial fast release due to the smaller size of nanoparticles and the drug was able to reach the interface of dissolution medium easily [35, 36]. The release profiles showed the cumulative drug release from 69.52-81.44 % in 10 hrs at pH 6.8. The increase in percent cumulative drug release with an increase in surfactant concentration could be attributed to a decrease in the particle size and an increase in the surface area. The release rate reduces as there is an increase in the molecular weight of polymers [37, 38].

3.9. Drug Release Kinetics

The drug release data of optimized batch of glibizide loaded Eudragit RS100 nanoparticles were fit to zero order, first order, and Higuchi and Korsmeyer-Peppas models. The value of correlation
Table 7. Values of correlation coefficients ($R^2$) calculated after fitting the release profile of optimized batch obtained using different mathematical models.

| S. No. | Model               | Value of $R^2$ |
|--------|---------------------|----------------|
| 1      | Zero-order          | 0.962          |
| 2      | First order         | 0.987          |
| 3      | Higuchi order       | 0.988          |
| 4      | Korsmeyer-Peppas model | 0.993        |

Fig. (11). TEM image of glipizide loaded rs 100 optimized batch.
The R² value of the optimized batch of Eudragit RS100 nanoparticles followed the Korsmeyer-Peppas model. Korsmeyer-Peppas model indicated that drug release followed a combination of diffusion as well as erosion mechanisms [36, 37].

3.10. Transmission Electron Microscopy

The particle size of the optimized batch was determined by TEM analysis and the patterns were found to be uniform in size and spherical in shape. The image of particles is shown in Fig. (11).

CONCLUSION

Glipizide loaded Eudragit RS100 NPs were prepared using the solvent evaporation method. 3² factorial design was employed for the design of formulation. As indicated by the study formulation of glipizide, Eudragit RS100 has the ability to modify the physicochemical characteristics of the drug. Using factorial design maximum entrapment efficiency with minimum particle size could be achieved with few experiments. The response surface plots and contour plots were studied to confirm the same. In vitro release was found to follow the first order Fickian diffusion kinetics. There was an increase in drug encapsulation efficiency. The DSC confirms there is a decrease in crystallinity in the nanoparticles formulations. The intermolecular interaction between drug and Eudragit RS100 was detected in the FT-IR spectrum of the prepared formulation.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

HUMAN AND ANIMAL RIGHTS

No Animals/Humans were used for studies that are the basis of this research.

CONSENT FOR PUBLICATION

Not applicable.

AVAILABILITY OF DATA AND MATERIALS

The authors confirm that the data supporting the findings of this research are available within the article.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

The author is highly thankful to the Chairman, Department of Pharmaceutical Sciences, for providing necessary facilities.

REFERENCES

[1] Dora CP, Singh SK, Kumar S, Datusalia AK, Deep A. Development and characterization of nanoparticles of glibenclamide by solvent displacement method. Acta Pol Pharm Drug Res 2010; 67 (3): 283-90.
[2] Baily CJ. Potential new treatments for type two diabetes. Tips 2000; 21: 259-65.
[3] Harlay CR. Glipizide GRTS has advantages over other second generation sulfonylurea. Clin Drug Invest 2002; 22: 575-84.
[4] Hesieh SH, Lin JD, Chang HY, Ho Ch, Liou MJ. Sustained release versus immediate release glipizide for the treatment of diabetes mellitus in Chinese patients: a randomized, double blind, double dummy, parallel group, 12 week clinical study. ClinTher 2006; 28: 1318-26.
[5] Venkateswarlu K and Shanthi A. Formulation and evaluation of sustained release glipizide matrix. IOSR J Pharm Biol Sci 2012; 2(5): 17-23.
[6] Muthu MS. Nanoparticles based on PLGA and its copolymer: an overview. Asian J Pharm 2009; 3: 266-73.
[7] Price J. Handbook of Pharmaceutical Excipients. The Pharmaceutical Press: London 2003; pp.1-917.
[8] Singh S, Neelam, Arora S, Singla VP. An overview of multifaceted significance of eudragit polymers in drug delivery systems. Asian J Pharm Clin Res 2015; 8(5): 1-6.
[9] Chowdary, KPR; Srinivasa, YR.; Design and in vitro evaluation of mucoadhesive controlled release oral tablet of glipizide. Indian J Pharm 2003; 65: 592-99.
[10] Singh B, Bhatowa R, Tripathi CB, Kapil R. Developing micro-/nanoparticulate drug delivery systems using “design of experiments”. Int J Pharm Invest 2011; 1(2): 75-81.
[11] Verma RK, Garg S. Development and evaluation of osmotically controlled oral delivery system of glipizide. Eur J Pharm Biopharm 2004; 57: 513-25.
[12] Myers RH, Montgomery DC. Response surface methodology: process and product optimization using designed experiments. New York: John Wiley & Sons 2002.
Preparation, Optimization and In vitro Evaluation

[13] Thombre AG, Denoto AR, Gibbes DC. Delivery of glipizide from asymmetric membrane capsules using encapsulated excipients. J control release 1999; 60: 333-41.

[14] Florence, AT. Issues in oral nanoparticle drug carrier uptake and targeting, J Drug Target 2004; 12: 65-70.

[15] Khafagy ES, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev 2007; 59(15): 1521-46.

[16] Patel JK, Patel RP, Amin AF, Patel MM. Formulation and evaluation of mucoadhesive glipizide microspheres. AAPS Pharm Sci Tech 2005; 6: 49-55.

[17] Harivardhan LR, Murthy RSR. Influence of polymerization technique and experimental variables on the particle properties and release kinetics of methotrexate from poly (butylcyanoacrylate) nanoparticles. Acta Pharm 2004; 54: 103-18.

[18] Florence A, Hillery A, Hussain N, Jani P. Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J Cont Rel 1995; 36(1-2): 39-46.

[19] Sonavane GS, Devarajan PV. Preparation of alginate nanoparticles using Eudragit E100 as a new complexing agent: development, in-vitro, and in-vivo evaluation. J Biomed Nanotechnol 2007; 3: 160-9.

[20] Zengshuan MA, Yeoh HH, Lim LY. Formulation pH modulates of insulin with chitosan nanoparticles. J Pharm Sci 2002; 91: 1396-404.

[21] Crowley MM, Schroeder B, Fredersdrof A, et al. Physicochemical properties and mechanism of drug release from ethylcellulose matrix tablets prepared by direct compression and hot-melt extrusion. Int J Pharm 2004; 269: 509-22.

[22] Ehtezazi T, Washington C, Melia CD. First order release rate from porous PLA microspheres with limited exit on the exterior surface. J Cont Rel 2000; 66: 27-38.

[23] Akil MA, Kartal-Hodzic A, Oksanen T, et al. Factorial design formulation optimization and in vitro characterization of curcumin-loaded PLGA nanoparticles for colon delivery. J Drug Deliv Sci Technol 2016; 32: 10-20.

[24] Lokhande A, Mishra S, Kulkarni R, Naik J. Formulation and evaluation of glipizide loaded nanoparticles. J Pharm Pharm Sci 2013; 5: 147-51.

[25] Nayak AK, Pal D, Santra K. Ispaghula mucilage-gellan mucoadhesive beads of metformin HCl: development by response surface methodology. Carbohydr Polym 2014; 107: 41-50.

[26] Malakar J, Nayak AK, Goswami S. Use of response surface methodology in the formulation and optimization of bisoprolol fumarate matrix tablets for sustained drug release. ISRN pharmacol 2012; 2012: 1-10.

[27] Nayak AK, Pal D, Santra K. Plantago ovata F. Mucilage-alginate mucoadhesive beads for controlled release of glibenclamide: development, optimization, and in vitro-in vivo evaluation. J Pharm 2013; 2013: 1-13.

[28] Shid RL, Dhole SN, Kulkarni N, Shid SL. Formulation and evaluation of nanosuspension delivery system for simvastatin. Int J Pharm Sci Nanotechnol 2014; 7: 2459-76.

[29] Naha PC, Byrne HJ, Panda AK. Role of polymeric excipients on controlled release profile of Glipizide from PLGA and Eudragit RS 100 Nanoparticles. J Nanopharma Drug Deliv 2013; 1(1): 74-81.

[30] Verma S, Singh SK, Verma PR. Fabrication of lipidic nanocarriers of loratadine for facilitated intestinal permeation using multivariate design approach. Drug Dev Ind Pharm 2016; 42(2): 288-306.

[31] Bera K, Khanam J, Mohanraj KP, Mazumder B. Design and evaluation of mucoadhesive beads of glipizide as a controlled release drug delivery system. J Microencapsul 2014; 31(3): 220-9.

[32] Rao ME, Swain S, Patra CN, Mund SP. Formulation Design, Optimization and Characterization of Eprosartan Mesylate Nanoparticles. Nanosci Nanotech Asia 2018; 5(1): 130-43.

[33] Petkar KC, Chavhan S, Kunda N, et al. Development of novel octanoyl chitosan nanoparticles for improved rifampicin pulmonary delivery: optimization by factorial design. AAPS PharmSciTech 2018; 31(1): 1-5.

[34] Verma U, Naik JB, Deshmukh R, Mishra S. Development of biodegradable glimepiride loaded chitosan nano particles: a factorial design approach. Curr Environ Eng 2018; 5(1): 68-77.

[35] Jain S, Jain A, Bhargav S. Formulation and evaluation of embelin loaded pectin nanoparticles for the treatment of diabetes. Pancreatology 2018; 18(4): S39.

[36] Reis CP, Neufeld RJ, Veiga F. Preparation of drug-loaded polymeric nanoparticles. In Nanomed Cancer Asia 2017; 2(1): 8-2.

[37] Landry F, Bazile D, Spenlehauer G, Veillard M, Kreuter J. Influence of the coating agents on the degradation of poly (D,L lactic acid) nanoparticles in model digestive fluids. S.T.P. Pharma Sci 1996; 6(3): 195-202.

[38] Parikh R, Parikh J, Dubey R, Soni H, Kapadia K. Poly (D,L-lactide-coglycolide) microspheres containing 5-fluorouracil: optimization of process parameters, A.A.P.S. PharmSciTech 2003; 4(2) E13.